-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$169.0647.95% Upside
Recent Analyst Forecasts and Stock Ratings
Sarepta Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Sarepta Therapeutics, Inc.?
Sarepta Therapeutics, Inc. has been rated by research analysts at Robert W. Baird, Cantor Fitzgerald, Jefferies, Evercore ISI, Piper Sandler, Barclays in the past 90 days.